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Abstract
The tumor-suppressor p53 undergoes extensive poly(-
ADP-ribosyl)ation early during apoptosis in human
osteosarcoma cells, and degradation of poly(ADP-
ribose) (PAR) attached to p53 coincides with poly(-
ADP-ribose)polymerase-1, (PARP-1) cleavage, and
expression of p53 target genes. The mechanism by
which poly(ADP-ribosyl)ation may regulate p53 func-
tion has now been investigated. Purified wild-type
PARP-1 catalyzed the poly(ADP-ribosyl ) of full - length
p53 in vitro. In gel supershift assays, poly(ADP-
ribosyl )ation suppressed p53 binding to its DNA
consensus sequence; however, when p53 remained
unmodified in the presence of inactive mutant PARP-1,
it retained sequence-specific DNA binding activity.
Poly(ADP-ribosyl)ation of p53 by PARP-1 during early
apoptosis in osteosarcoma cells also inhibited p53
interaction with its DNA consensus sequence; thus,
poly(ADP-ribosyl )ation may represent a novel means
for regulating transcriptional activation by p53 in vivo.
Neoplasia (2001) 3, 179–188.
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Introduction
One of the earliest nuclear events triggered by the DNA
strand breakage associated with DNA repair, DNA repli-
cation, and apoptosis is the poly(ADP-ribosyl )ation of
various DNA-binding proteins [1–6]. Utilizing NAD as a
substrate, this posttranslational modification is catalyzed by
a poly(ADP-ribose) polymerase (PARP) gene family, which
now includes PARP-1, PARP-2, and PARP-3 [7,8 ]. PARP-
1 is activated by binding to DNA ends through its two zinc
fingers [9,10] and undergoes extensive autopoly(ADP-
ribosyl )ation in a central automodification domain through
an ester linkage between poly(ADP-ribose) (PAR) homo-
polymers and 15 glutamic acid residues in this domain
[9,11]. In contrast, PARP-2 and PARP-3 lack DNA binding
and automodification domains [7] and account for the
residual PARP activity in PARP-1–deficient cells [8,12].
Given that each PARP-1 molecule has 18 to 28 automodi-
fication sites [13], PAR chains of up to 200 residues are
covalently bound mainly to PARP-1 and, to a lesser extent,
to other nuclear acceptor proteins. Restricted mostly to the
potential targets located adjacent to DNA breaks [14],
poly(ADP-ribosyl )ation of nuclear proteins in response to
DNA strand breakage is transient in intact cells. The half - life
of PAR is only 1 to 2 min as a result of its rapid degradation by
PAR glycohydrolase [15].
The nuclear protein substrates of PARP-1 include
histones, DNA topoisomerases I and II [16,17], SV40 large
T antigen [18], DNA polymerases  and , proliferating cell
nuclear antigen, and 15 components of the DNA synthe-
some [17]. Poly(ADP-ribosyl )ation of enzymes, such as
DNA polymerases  and  [19,20] and topoisomerases I
and II [16,21,22], modulates their activities; in most
instances, such modification inhibits enzyme activity, pre-
sumably as a result of a marked decrease in affinity of the
proteins for DNA caused by electrostatic repulsion between
the negatively charged DNA and PAR. Extensive automo-
dification of PARP-1 also allows it to cycle on and off DNA
ends during DNA repair in vitro [23–26]; whereas unmodi-
fied PARP-1 binds tightly to DNA ends and is thought to
interfere with repair, the subsequent release of PARP-1
triggered by automodification allows access of repair
enzymes to the DNA. PARP-1 and/or poly(ADP-ribosyl )a-
tion are implicated in base excision repair (BER) [27–31],
and PARP-1 has been shown to interact with components
of the BER complex ( i.e., XRCC1, DNA pol , and DNA
ligase lll ) [30,32].
We have recently shown that a transient poly(ADP-
ribosyl )ation of nuclear proteins occurs early during apopto-
sis, before commitment to cell death, in various cell lines and
with different inducers of apoptosis, and that this event is
followed by cleavage and inactivation of PARP-1 [6,33,34].
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BRIEF ARTICLE
Prevention of this early PARP-1 activation by expression of
PARP antisense RNA or by PARP-1 gene knockout blocks
progression of apoptosis, thus correlating this early
poly(ADP-ribosyl )ation with later events in the cell death
cascade [6]. The impairment of apoptosis, as well as a lack
of expression of the tumor-suppressor proteins p53 and Rb
in cells of PARP-1 knockout mice, were also recently shown
by comparative genomic hybridization analysis to be
associated with genomic instability [35]. The expression of
p53 is induced by a variety of proapoptotic stimuli and is
required for apoptosis in many cell types [36]; transcriptional
activation of target genes and interaction with other proteins
are thought to contribute to p53-dependent apoptosis. A
functional association of PARP and p53 has recently been
suggested by coimmunoprecipitation of each protein in vitro
by antibodies to the other [37,38]. Together with a variety of
other nuclear proteins, p53 undergoes extensive poly(ADP-
ribosyl )ation early during spontaneous apoptosis in human
osteosarcoma cells; this event is accompanied by a marked
increase in the intracellular abundance of p53 [39].
Subsequent degradation of PAR covalently attached to p53
occurs simultaneously with the onset of proteolytic process-
ing and activation of caspase-3, caspase-3–mediated
cleavage of PARP-1, and internucleosomal DNA fragmen-
tation. The removal of PAR from p53 during apoptosis also
coincides with a marked induction of expression of the p53-
responsive genes encoding the proapoptotic proteins Bax
and Fas [39], suggesting that poly(ADP-ribosyl )ation may
regulate p53 function.
It has been shown that p53 is poly(ADP-ribosyl )ated by
partially purified PARP-1 in vitro, and that binding of p53 to a
specific DNA consensus sequence prevents its covalent
modification [40]. We now show that poly(ADP-ribosyl )a-
tion of p53 with PARP-1 in vitro and in vivo inhibits the
binding of p53 to its DNA consensus sequence, providing
mechanistic insights on how poly(ADP-ribosyl )ation affects
p53 functions in vivo. These results suggest that, similar to
the mechanism proposed for PARP-1 itself, p53 may cycle
on and off its DNA consensus sequences depending on the
extent of their poly(ADP-ribosyl )ation. PARP-1 may thus
regulate the transcriptional activation of target genes by p53
during p53-dependent apoptosis.
Materials and Methods
Recombinant p53: Expression and Purification of
Recombinant Wild-Type and Inactive Mutant
PARP-1 Proteins
Purified recombinant p53, an 80-kDa GST fusion protein
of full - length human p53 (amino acids 1–393) expressed
in Escherichia coli and purified by Ni resin column
chromatography, and GST were obtained from Santa Cruz
Biotechnology. Recombinant human wild- type PARP-1
and a catalytically inactive PARP-1 mutant were expressed
as six histidine- tagged fusion proteins in E. coli, purified to
>95% homogeneity by Ni resin column chromatography,
and renatured. The catalytically inactive PARP-1 mutant
bears a single-point mutation at Lys893, which has been
shown to be critical for activity [41], introduced by site-
directed mutagenesis of the catalytic domain of human
PARP-1.
Immunoprecipitation, Immunodepletion, and Immunoblot
Analysis
For immunoblot analysis, sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and transfer of
proteins to nitrocellulose membranes were performed
according to standard procedures. The membranes were
stained with Ponceau S (0.1%) to confirm equal loading and
transfer of proteins, and were then incubated, unless
indicated otherwise, with mouse monoclonal antibodies
(mAbs) to p53 (1:200 dilution) (PAb421; Calbiochem), to
PAR (1:250 dilution) [42], or to glutathione S- transferase
(GST) (1:200 dilution) (Santa Cruz Biotechnology), or with
polyclonal antibodies (pAb) to PARP-1 (1:1000 dilution)
(Pharmingen). Immune complexes were detected with
appropriate horseradish peroxidase–conjugated secondary
antibodies (1:3000 dilution) and enhanced chemilumines-
cence (Pierce).
Immunoprecipitation and immunodepletion were per-
formed as described previously [43], with slight modifica-
tions. Equal amounts of poly(ADP-ribosyl )ation reaction
mixtures or of cell extracts (10 g protein) were precleared
by incubation for 30 minutes at 48C in 200 l of EBC buffer
[50 mM Tris–HCl (pH 8.0), 120 mM NaCl, 0.5% NP-40,
aprotinin (0.1 T IU/ml) ] containing control mouse or rabbit
(as appropriate) IgG (1 g) and protein A/G agarose beads
(20 l; Pharmacia). After centrifugation, PARP-1 was
immunodepleted from the supernatants by incubation for 1
hour at 48C with anti -PARP (1 g; Pharmingen) and protein
A/G agarose beads (20 l; Pharmacia). After centrifugation,
the resulting supernatants were subjected to either immu-
noprecipitation or electrophoretic mobility supershift assays
(EMSSA). Immunoprecipitation was performed by incuba-
tion of supernatants for 1 hour at 48C in 500 l of NET-N
buffer [20 mM Tris–HCl (pH 8.0), 100 mM NaCl, 1 mM
EDTA, 0.5% NP-40] containing either mAb to p53 (Ab-1;
Calbiochem) or control IgG (each at a concentration of 2 g/
ml). After addition of protein A/G agarose beads (20 l ), the
mixtures were incubated for 1 hour at 48C. The beads were
then separated by centrifugation and washed extensively
with NET-N buffer, after which bound proteins were
subjected to immunoblot analysis, first with the mAb to
PAR and then with pAb to p53 (Calbiochem) or to PARP.
Poly(ADP-ribosyl )ation of p53 In Vitro by Purified
Recombinant PARP-1
Purified recombinant p53 (1 g) was incubated for 30
minutes at 378C with purified recombinant wild - type or
mutant PARP-1 (0.1 g) in a reaction mixture (50 l )
containing 50 mM Tris–HCl (pH 7.8), 25 mM MgCl2, 1 mM
dithiothreitol, 4 g of nicked calf thymus DNA, and 100 M
NAD. The reaction was terminated by the addition of SDS-
PAGE sample buffer and subjected to immunoblot analysis
with anti -PAR. In some experiments, the poly(ADP-ribosy-
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l )ation of p53 was assessed by incubation of these proteins
for 1, 3, or 5 minutes at 378C in the same reaction mixture but
containing 1 M [32P]NAD in place of 100 M NAD; the
mixtures were subsequently analyzed by SDS-PAGE and
autoradiography.
EMSSA
EMSSA analysis was performed according to standard
procedures, with slight modifications. Oligonucleotides con-
taining p53 consensus binding sequences (Santa Cruz
Biotechnology) were labeled at their 50 ends with
[ -32P]ATP by T4 polynucleotide kinase, and were purified
by phenol–chloroform extraction and ethanol precipitation.
After incubation with excess poly(dI:dC) (10 g) and bovine
serum albumin (10 g) in DNA binding buffer (Promega),
cell extracts (10 g of protein) or poly(ADP-ribosyl )ation
reaction mixtures (20 l ) were immunodepleted of PARP-1
as described above. Given that recombinant p53 has been
shown to be essentially unable to bind its DNA consensus
sequence in EMSSAs unless binding is first selectively
activated by mAb to p53 PAb421 [44], gel supershift assays
were performed by incubation of the PARP-depleted super-
natants for 1 hour on ice in a final volume of 40 l with mAb to
p53 (1 g) and then for 15 minutes at room temperature with
the 32P- labeled DNA probe (100,000 cpm). The DNA–
protein complexes were then analyzed by electrophoresis on
native 5% polyacrylamide gels in Tris–borate–EDTA buffer,
followed by autoradiography.
Results
Poly(ADP-ribosyl )ation of p53 by Purified Recombinant
PARP-1 In Vitro
We examined the mechanism by which poly(ADP-
ribosyl )ation may regulate p53 function with the use of
purified recombinant proteins in vitro. The purifiedGST fusion
protein containing full - length p53 was analyzed by immuno-
blot analysis with anti -p53. These antibodies specifically
recognized endogenous p53 in human osteosarcoma cell
extracts and the 80-kDa GST-p53(1–393) fusion protein,
consistent with the expectedmolecular mass of GST fused to
full - length human wild- type p53 (Figure 1A ). Similarly,
immunoblot analysis with anti -PARP of purified recombinant
wild- type PARP-1 and a catalytically inactive mutant, both
expressed as histidine- tagged fusion proteins, revealed
120-kDa immunoreactive proteins (Figure 1B ). Measure-
ment of the incorporation of [ 32P]NAD into acid- insoluble
acceptors verified that the wild- type PARP-1 protein was
catalytically active (1.9103 nmol /min per milligram), while
the mutant was not (8 nmol /min per milligram) (Figure 1C ).
Incubation of GST-p53(1–393) with purified recombi-
nant wild - type PARP-1, but not with the mutant enzyme, in
the presence of 100 M NAD and nicked DNA resulted in
poly(ADP-ribosyl )ation of the fusion protein, as revealed by
immunoblot analysis with anti -PAR (Figure 2A ). One
unavoidable technical complication of these experiments
with purified proteins is that PARP-1 also undergoes
automodification, adding to the complexity of the immuno-
logical analyses. The immunoreactive band migrating just
below the position corresponding to 108 kDa (which was
not evident in the reaction mixture lacking p53 fusion protein)
likely corresponds to poly(ADP-ribosyl )ated p53; the immu-
noreactive bands migrating at positions corresponding to
108 to >200 kDa likely include automodified PARP-1 and
long-chain, highly modified p53. An 80-kDa band in the
anti -PAR immunoblot coincided with the GST-p53(1–393)
fusion protein as revealed by reprobing the blot with anti -
p53. Poly(ADP-ribosyl )ation of GST-p53(1–393) by wild-
type PARP-1, but not by the mutant protein, was also
demonstrated by incubation in the presence of 1 M
[32P]NAD and autoradiography (Figure 2B ). Most of the
radioactivities evident at 122 kDa and in two lower bands
reflected automodified PARP-1 and its degradation prod-
ucts, given that these bands were also present in the lane
corresponding to wild - type PARP-1 alone; a band at 80
kDa present in the samples containing GST-p53(1–393)
and wild- type PARP-1 thus corresponds to the poly(ADP-
ribosyl )ated GST–p53 fusion protein. As expected, although
there was 10- fold more p53 than PARP-1, PARP-1 was the
main acceptor protein in these reactions, with heteromodi-
fication of p53 occurring at a lesser extent. This preferential
automodification of PARP-1 is attributed to the presence of
28 automodification sites (glutamate residues) for the
covalent attachment of PAR homopolymers of up to 200
residues long [9,11,13]. In contrast, binding experiments
with free PAR and p53 revealed only two PAR-binding sites
in the sequence-specific core DNA binding domain of p53
and a third site in the oligomerization domain [45]. There is
no apparent increase in intensity of the bands (PAR
covalently bound to PARP or to p53) with time because,
under the conditions of the in vitro poly(ADP-ribosyl )ation
used in this experiment (with 1 M 32P-NAD), the reaction is
only linear for less than 1 minute; at this NAD concentration,
only short polymers are covalently bound to acceptor
proteins; thus, the molecular weight of PARP stays around
116 kDa. However, an increase in size of p53, as revealed by
a shift in mobility to a slightly higher position in the gel,
indicates addition of longer polymer chains with time.
To confirm that GST-p53(1–393) is poly(ADP-ribosy-
l )ated by wild- type PARP-1 in vitro, the reaction mixture
containing nonradioactive NAD was immunodepleted of
PARP by immunoprecipitation with anti -PARP, and the
resulting supernatant was subjected to immunoprecipitation
with anti -p53. Immunoblot analysis of the resulting precip-
itates with anti -PAR revealed extensive poly(ADP-ribosy-
l )ation of GST-p53(1–393) in the presence of wild- type
PARP-1, but not with the mutant enzyme (Figure 2C ).
Reprobing of the immunoblot with anti -p53 and anti -PARP
verified that the modified protein was indeed p53 and not
PARP-1 (Figure 2C ). When immunoprecipitation of the
PARP-1–depleted supernatant was performed with control
IgG, immunoblot analysis with anti -p53 failed to detect any
specific immunoreactivity (Figure 2C ). To verify that it was
the p53 portion, and not the GST component, of GST-p53
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that was poly(ADP-ribosyl )ated by PARP-1, purified
recombinant GST was incubated with wild - type and mutant
PARP-1 in the presence of NAD. Immunoblot analysis with
anti -PAR and anti -GST revealed that wild - type PARP-1
was the only protein to undergo poly(ADP-ribosyl )ation, a
reaction that was inhibited by the specific PARP inhibitor 3-
aminobenzamide (Figure 2D ).
Poly(ADP-ribosyl )ation of p53 by PARP-1 In Vitro Blocks
Binding to its DNA Consensus Sequence
To investigate whether poly(ADP-ribosyl )ation of p53 by
PARP-1 affects binding to the corresponding DNA con-
sensus sequence element, we performed gel supershift
assays with a 32P- labeled 30-bp oligonucleotide containing
the specific p53-binding sequence as the DNA probe.
Recombinant p53 has been shown to be essentially inactive
in sequence-specific DNA binding in EMSSAs, but binding is
strongly and selectively activated by mAb to p53 PAb421
[44]. Thus, in gel supershift assays, poly(ADP-ribosyl )ation
reaction mixtures were immunodepleted of PARP-1, incu-
bated first with mAb to p53 and then with the DNA probe, and
analyzed by electrophoresis and autoradiography.
Binding of unmodified GST-p53(1–393) to the 32P-
labeled probe was apparent by the appearance of a distinct
shifted band corresponding to the p53–antibody–DNA
complex (Figure 3A ). The specificity of the interaction was
confirmed by the observations that incubation of GST-
p53(1–393) with an unrelated control oligonucleotide (NF-
Figure 1. Immunoblot analysis of recombinant p53 and PARP -1 proteins; catalytic activities of wild - type and mutant PARP-1. (A ) Immunoblot analysis with anti -
p53 of purified GST -p53( 1–393 ) (0.1 g ) and of an osteosarcoma cell extract ( 30 g of protein ). (B ) Immunoblot analysis with anti -PARP of purified wild - type
(wt ) and catalytically inactive mutant (mut ) PARP-1. The positions of molecular size standards ( in kDa ) and of the proteins (arrows ) are indicated. (C ) Relative
catalytic activities of wild - type and mutant PARP-1 were determined by incubation of PARP-1 (0.1 g ) for 1 minute at 25 8C in a reaction mixture (50 l ) containing
50 mM Tris –HCl ( pH 7.8 ), 25 mMMgCl2, 1 mM dithiothreitol, 4 g of activated DNA, 100 MNAD, and 1 l [
32P ]NAD (2 mCi /mmol ), as described in Materials and
Methods section. Data are expressed as nanomoles of [ 32P ]NAD incorporated per minute per milligram of protein, and are means of triplicate determinations from a
representative experiment.
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B consensus sequence) did not result in the formation of a
DNA–protein complex (Figure 3A ), and that binding of the
p53 fusion protein to the p53-binding sequence was
inhibited in a concentration-dependent manner by the
presence of excess nonradioactive-specific probe (Figure
3B ). Poly(ADP-ribosyl )ation of GST-p53(1–393) by wild-
type PARP-1 in the presence of NAD markedly inhibited the
binding of the p53 fusion protein to the specific DNA probe
(Figure 3A ). In contrast, preincubation of GST-p53(1–393)
with mutant PARP-1 and NAD did not affect the formation of
the specific DNA–protein complex. The shifted bands were
not due to binding of any remaining PARP-1 in the reaction
Figure 2. Poly(ADP - ribosyl )ation of GST-p53( 1–393 ) and GST by wild - type PARP -1 in vitro. (A ) Recombinant wild - type or mutant PARP-1 (0.1 g ) was
incubated for 30 minutes at 37 8C in the presence of 100 M NAD and in the absence or presence of GST -p53( 1–393 ) ( 1 g ), as indicated. The reaction mixtures
were then subjected to immunoblot analysis with anti -PAR ( left panel ), after which the blot was stripped of antibodies and reprobed with anti - p53 ( right panel ).
Arrows: p53 -PAR, poly(ADP - ribosyl )ated p53 fusion protein; GST -p53, GST -p53(1–393 ). (B ) Recombinant wild - type or mutant PARP-1 (0.1 g ) was
incubated for the indicated times at 37 8C in the presence of 1 M [32P ]NAD and in the absence or presence of GST -p53(1–393 ) ( 1 g ). The reaction mixtures
were then subjected to SDS-PAGE and autoradiography. Arrows indicate the positions of poly(ADP- ribosyl )ated PARP-1 and p53 fusion protein. (C ) GST -
p53( 1–393 ) was incubated in the absence or presence of wild - type or mutant PARP -1 as in (A ). The reaction mixtures were immunodepleted of PARP-1 and then
subjected to immunoprecipitation with anti - p53 or with control IgG, as indicated. The resulting immunocomplexes were subjected to immunoblot analysis with anti -
PAR, after which the blot was stripped of antibodies and reprobed with anti - p53 and then with anti -PARP, as indicated. (D ) Purified GST (1 g ) was incubated for
30 minutes at 37 8C in the presence of 100 MNAD and in the absence or presence of wild - type or mutant PARP -1 (0.1 g ) and 1mM 3-aminobenzamide (3 -AB ),
as indicated. The reaction mixtures were then subjected to immunoblot analysis with anti -PAR ( left panel ), after which the blot was stripped of antibodies and
reprobed with anti -GST ( right panel ).
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mixtures to the DNA probe because wild- type or mutant
PARP-1, in the absence of p53, did not bind to the p53
consensus sequence. Similar EMSSA analysis has also
previously shown that free PAR noncovalently attached to
p53 in vitro blocks the sequence-specific interaction of p53
with its consensus binding sequence [45].
Poly(ADP-ribosyl )ation of p53 at an Early Stage of
Apoptosis in Osteosarcoma Cells Inhibits Binding to its
DNA Consensus Sequence In Vitro
Degradation of PAR attached to p53 coincides with the
onset of caspase-3–mediated PARP-1 cleavage, internu-
cleosomal DNA fragmentation, and activation of the p53
target genes encoding Bax and Fas during spontaneous
apoptosis in human osteosarcoma cells [39], suggesting
that poly(ADP-ribosyl )ation may regulate p53 function.
Extracts of osteosarcoma cells prepared before (day 1),
after (day 5), and at (day 3) the peak of poly(ADP-
ribosyl )ation that occurs at the early reversible stage of
apoptosis were subjected to immunoprecipitation with anti -
p53 and immunoblot analysis with anti -PAR and anti -p53.
Although endogenous levels of p53 protein were significantly
increased at days 3 and 5, transient extensive poly(ADP-
ribosyl )ation of endogenous p53 was apparent only at day 3
(Figure 4A ). Immunoblot analysis of osteosarcoma cell
extracts at different stages of apoptosis with antibodies to
Bax and Fas further showed that expression of these p53-
responsive genes ( lower panel ) was negligible when p53
was in a poly(ADP-ribosyl )ated state (day 3), but increased
at day 5 when p53 was largely unmodified (middle panel ).
Thus, poly(ADP-ribosyl )ation may modulate p53 function
early in apoptosis perhaps by altering its binding to specific
DNA sequences in the promoters of p53 target genes such
as Bax and Fas. The effect of poly(ADP-ribosyl )ation on the
binding of p53 to its DNA consensus sequence was therefore
Figure 3. Effect of poly(ADP- ribosyl )ation of GST-p53( 1–393 ) by PARP-1
in vitro on binding of p53 to its DNA consensus sequence. (A ) After incubation
for 30 minutes at 37 8C, poly(ADP - ribosyl )ation reaction mixtures containing
NAD and the indicated combinations of GST -p53( 1–393 ) and wild - type or
mutant PARP-1 were immunodepleted of PARP -1 and then subjected to
EMSSA by incubation first with anti - p53 and then with a 32P - labeled 30 -bp
oligonucleotide probe corresponding to the consensus p53 -binding sequence
(or with a control probe corresponding to the NF -B–binding sequence ). (B )
EMSSA analysis was performed as in (A ), with the exception that the
incubation with the 32P - labeled p53 - specific probe was performed in the
absence or presence of 10 or 50 excesses of the same unlabeled probe.
The positions of free DNA probe and the antibody–p53–DNA complex are
indicated.
Figure 4. Effect of poly(ADP - ribosyl )ation of p53 during early apoptosis in
osteosarcoma cells on p53 binding to its DNA consensus sequence in vitro.
(A ) Cell extracts from osteosarcoma cells before ( day 1 ), after ( day 5 ), and at
( day 3 ) the peak of poly(ADP - ribosyl )ation during the early stage of
apoptosis were subjected to immunoblot analysis with antibodies to Bax and
Fas ( lower panel ) and to immunoprecipitation with anti - p53. After immuno-
precipitation with anti - p53, the resulting immunocomplexes were then
subjected to immunoblot analysis with anti - p53 (upper panel ) and anti -
PAR (middle panel ). (B ) Osteosarcoma cell extracts prepared before (D1 ),
after (D5 ), and at the peak of poly(ADP - ribosyl )ation (D3 ) were subjected to
gel supershift assays with anti - p53 and the 32P - labeled 30 -bp oligonucleo-
tide containing the consensus p53 -binding sequence. Control EMSSAs were
also performed in the absence of cell extract, or with an unrelated control
oligonucleotide (NF -B consensus sequence ) to confirm specificity of
binding.
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examined by gel supershift assays with cell extracts
prepared before (day 1), after (day 5), and at (day 3) the
peak of poly(ADP-ribosyl )ation. Consistent with our in vitro
results with purified proteins, extensive poly(ADP-ribosyl )a-
tion of endogenous p53 by PARP-1 (at day 3) in intact cells
also inhibited p53 binding to its specific DNA consensus
sequence (Figure 4B ). The specificity of the interaction was
confirmed by the incubation of cell extract (D5) with an
unrelated control oligonucleotide (NF-B consensus
sequence), which did not result in the formation of a DNA–
antibody–protein complex (Figure 4B, right panel ). Thus, by
modulating p53 binding to its DNA consensus sequence
while in a negatively charged modified state, poly(ADP-
ribosyl )ation may represent an additional posttranslational
modification besides phosphorylation [46] and acetylation
[47], by which p53-dependent transcription may be tran-
siently regulated in vivo.
Discussion
We have previously shown that a transient poly(ADP-
ribosyl )ation of nuclear proteins occurs early during apopto-
sis, before commitment to cell death, in 3T3-L1, HL-60,
Jurkat, and osteosarcoma cells and in immortalized PARP-
1+ / + fibroblasts with different inducers of apoptosis. This
transient PARP-1 activation precedes the proteolytic pro-
cessing of caspase 3, caspase-mediated cleavage of
PARP-1 and the DNA fragmentation factor (DFF45), and
internucleosomal DNA fragmentation [6,33,34]. Given that
the activity of PARP is dependent on DNA strand breaks, this
early nuclear poly(ADP-ribosyl )ation during apoptosis is
consistent with the appearance of large (1 Mb) chromatin
fragments at this reversible stage [48], as well as a marked
decrease in NAD concentration indicative of increased PAR
synthesis, and a subsequent recovery in NAD levels before
internucleosomal DNA cleavage [49]. PARP activation also
occurs during apoptosis induced by various DNA-damaging
agents, such as alkylating agents, topoisomerase inhibitors,
adriamycin, X-rays, ultraviolet radiation, mitomycin C, and
cisplatin [50–54]. Progression of Fas-mediated apoptosis is
blocked by prevention of this early PARP-1 activation by
expression of PARP antisense RNA or by PARP-1 gene
knockout, thus correlating this early poly(ADP-ribosyl )ation
with later events in the cell death cascade [6].
We recently proposed a model, summarized in Figure 5,
whereby PARP-1 and poly(ADP-ribosyl )ation may play a
role in an ‘‘amplification loop’’ towards caspase activation
and downstream apoptotic events [34]. Stimulation of the
Fas receptor induces the gradual release of mitochondrial
factors, such as the apoptosis- inducing factor (AIF), that
translocates from the mitochondrial intermembrane space to
the nucleus and induces low levels of caspase- independent
cleavage of chromatin into large 50-kb fragments [55].
These large DNA breaks can stimulate PARP activity, rapidly
decreasing NAD and ATP levels, which contributes to both
receptor and mitochondrial pathways of apoptosis. Partial
depletion of ATP (10–65% of the control ) has been shown
to upregulate Fas, Fas ligand, and Fas-associating protein
with the death domain (FADD), resulting in induction of
caspase-8 and caspase-3 activity [56]. Binding of Fas to
Fas ligand recruits FADD via shared protein motifs (death
domains), resulting in subsequent activation or amplification
of the caspase cascade leading to apoptosis. Further
depletion of ATP below a threshold level inhibits later events
in apoptosis [57]; thus, subsequent degradation of PARP by
caspase-3- like proteases may prevent depletion of NAD
and ATP below this critical level as well as release certain
nuclear proteins, such as endonucleases [58,59] or p53,
from poly(ADP-ribosyl )ation- induced inhibition.
Apoptosis in osteosarcoma cells is associated with
accumulation of p53 early in the death program, presumably
due to induced expression of the protein or stabilization by
inhibition of p53 degradation via modification of the protein
[39]. Immunoprecipitation experiments further revealed that
p53 undergoes extensive poly(ADP-ribosyl )ation during the
transient burst of PAR synthesis at the early stages of
apoptosis, and subsequent degradation of PAR covalently
attached to p53 coincides with caspase-3–mediated
cleavage of PARP-1 and expression of the p53- responsive
genes encoding Bax and Fas [39]. Induction of Bax
expression may influence the decision to commit to
apoptosis since homodimerization of Bax promotes cell
death and heterodimerization of Bax with Bcl2 inhibits the
antiapoptotic function of Bcl2 [60]. Wild- type p53 also
upregulates Fas expression during chemotherapy- induced
apoptosis, and p53-responsive elements were recently
identified within the first intron and the promoter of the
Fas gene [61]. Furthermore, p53 activation transiently
increases surface Fas expression by enhancing intracellular
transport from the Golgi complex, induces Fas–FADD
binding, and transiently sensitizes cells to Fas- induced
apoptosis [62]. The simultaneous removal of PAR from
modified p53 and upregulation of Bax and Fas expression
suggested that poly(ADP-ribosyl )ation may transiently
inhibit the transactivation activity of p53 early during
apoptosis; caspase-mediated PARP-1 cleavage may sub-
sequently release p53 from such inhibition when the cells
become irreversibly committed to death. Additionally, a
polymer binding site in p53 localized near a proteolytic
cleavage site [45] suggests that PAR binding could protect
this sequence from proteolysis, given that similar protection
has been noted after binding of antibodies adjacent to this
region [63]. Thus, the poly(ADP-ribosyl )ation of p53 early
in apoptosis could also play a role in p53 accumulation by
protecting the protein from proteolytic degradation.
It is also possible that poly(ADP-ribosyl )ation contributes
indirectly to the regulation of p53, given that such modifica-
tion by PARP-1 of DNA-dependent protein kinase stim-
ulates the activity of this enzyme [64], which in turn regulates
p53 function by phosphorylation. With the use of purified
proteins in vitro, we have now shown that poly(ADP-
ribosyl )ation of p53 by PARP-1 inhibits the interaction of
p53 with its DNA consensus sequence. Furthermore,
poly(ADP-ribosyl )ation of endogenous p53 by PARP-1
during the early stage of apoptosis in human osteosarcoma
cells also inhibited the binding of p53 to its consensus
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binding sequence. These results provide mechanistic insight
on how poly(ADP-ribosyl )ation may affect p53 function in
vivo. The PARP-1–mediated covalent attachment of PAR to
p53 presumably occurs on glutamic acid residues within p53.
Consistent with these results, free PAR polymer non-
covalently bound to p53 in vitro blocks its specific binding
to the cognate DNA consensus sequence, and binding sites
for free PAR have been mapped to two sites in the
sequence-specific DNA-binding domain of p53 [45]. Our
data thus indicate that transient poly(ADP-ribosyl )ation of
p53 by PARP-1 may contribute to regulation of p53 function
by inhibiting the binding of p53 to its target sequence in the
promoters of p53-responsive genes, presumably as a result
of the negative charge conferred by the PAR modification,
and that it thereby transiently prevents activation of these
genes by p53. Although the suppression of p53 binding to its
DNA consensus sequence following extensive poly(ADP-
ribosyl )ation in vitro is not surprising, it is interesting to note
that p53 modified by PARP-1 in vivo does not bind its DNA
consensus sequence, consequently blocking expression of
p53-responsive genes Bax and Fas, which implies that most
of the p53 are poly(ADP-ribosyl )ated at this early reversible
stage of apoptosis.
The roles of PARP-1 in gene transcription may be
mediated, in part, by its effects on chromatin structure, given
that PARP-1 depletion by expression of antisense RNA
markedly alters the organization of chromatin [29]. PARP-1
has been implicated to play a dual role in the regulation of
transcription. PARP-1, in the absence of NAD, is suggested
to enhance activator -dependent transcription by interacting
with RNA polymerase II–associated factors [65]. Similarly,
PARP-1 binds to transcription enhancer factor 1 (TEF1), and
therebypromotesmuscle-specific gene transcription [66], as
well as to the transcription factor AP-2, and thereby acts as a
Figure 5. PARP -1 activation and cleavage in an ‘‘amplification loop’’ toward caspase activation and downstream apoptotic events. Stimulation of the Fas receptor
induces the release of mitochondrial factors, such as AIF, that translocates to the nucleus and induces caspase - independent chromatin cleavage into large 50 - kb
fragments. These large DNA breaks activate PARP, rapidly decreasing NAD and ATP levels, which contributes to both receptor and mitochondrial pathways of
apoptosis. Partial depletion of ATP further upregulates Fas, Fas ligand, and FADD; binding of Fas to Fas ligand recruits FADD, resulting in subsequent activation or
amplification of the caspase cascade leading to apoptosis. Subsequent cleavage of PARP by caspase -3 prevents depletion of NAD and ATP below a critical level as
well as releases certain nuclear proteins, such as Ca2+ –Mg2+ –dependent endonucleases and p53, from poly(ADP- ribosyl )ation - induced inhibition.
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coactivator in AP-2–mediated transcription [67]. PARP-1
also functions as a coactivator of the retroviral transcriptional
activator Tax [68]. Similarly, we recently demonstrated that
PARP-1 plays a role in the induction of expression of the
transcription factor E2F-1 by increasing the promoter activity
of the gene during reentry into S-phase [20,69].
Although, as described above, PARP-1 acts as a positive
cofactor for transcription in the absence of NAD, its activation
in the presence of NAD inhibits RNA polymerase II–
dependent transcription [65]. PARP-1–dependent inhibition
of transcription is mediated by the poly(ADP-ribosyl )ation of
various transcription factors, which prevents the formation of
active transcription complexes [70]. The basal transcription
factor TFIIF as well as TEF1 and the transcription factors
YY1, SP-1, and CREB are substrates for poly(ADP-
ribosyl )ation [66,70,71]. Similar to the effects of this
modification on p53 demonstrated in the present study,
poly(ADP-ribosyl )ation of these proteins prevents their
binding to the respective DNA consensus sequences [70].
These various transcription factors are specific substrates
for poly(ADP-ribosyl )ation, given that other proteins, includ-
ing TBP, TFIIB, c-Jun, and AP-2, have been shown to be
ineffective PARP-1 substrates under the same conditions
[70,71]. In a manner similar to that of the cycling of PARP-1
on and off DNA ends during DNA repair in vitro [23–26], it is
thus possible that p53 may cycle on and off its corresponding
DNA consensus sequence depending on the extent of its
poly(ADP-ribosyl )ation. Such a mechanism would thus
constitute a novel means for regulating transcriptional
activation of target genes by p53 in vivo.
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